Cybrexa Therapeutics Announces Positive Final Data at ESMO 2024 from Phase 1 Study of Peptide Drug Conjugate CBX-12 in Advanced Solid Tumors
September 16, 2024 06:30 ET
|
Cybrexa Therapeutics
Cybrexa Therapeutics Announces Positive Final Data at ESMO 2024 from Phase 1 Study of Peptide Drug Conjugate CBX-12 in Advanced Solid Tumors
Grupo Aeroportuario del Pacifico Reports in August 2024 a Passenger Traffic Decrease of 7.2% Compared to 2023
September 04, 2024 19:14 ET
|
Grupo Aeroportuario del Pacífico, S.A.B. de C.V.
GUADALAJARA, Mexico, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Grupo Aeroportuario del Pacífico, S.A.B. de C.V., (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) announces preliminary terminal passenger...
Grupo Aeroportuario del Pacifico Reports in July 2024 a Passenger Traffic Decrease of 5.6% Compared to 2023
August 05, 2024 22:01 ET
|
Grupo Aeroportuario del Pacífico, S.A.B. de C.V.
GUADALAJARA, Mexico, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Grupo Aeroportuario del Pacífico, S.A.B. de C.V., (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) announces preliminary terminal passenger...
Grupo Aeroportuario del Pacifico Announces Results for the Second Quarter of 2024
July 22, 2024 21:36 ET
|
Grupo Aeroportuario del Pacífico, S.A.B. de C.V.
GUADALAJARA, Mexico, July 22, 2024 (GLOBE NEWSWIRE) -- Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) reports its consolidated results for the second...
Raphael Pharmaceutical Issues Letter to Shareholders
July 09, 2024 08:30 ET
|
Raphael Pharmaceutical Inc
Highlights Company’s exclusive relationship with Rambam Health Care Campus, differentiated cannabinoid-based technology platform, promising lead product candidate for rheumatoid arthritis, recently...
Grupo Aeroportuario del Pacifico Reports in June 2024 a Passenger Traffic Decrease of 1.9% Compared To 2023
July 05, 2024 16:23 ET
|
Grupo Aeroportuario del Pacífico, S.A.B. de C.V.
GUADALAJARA, Mexico, July 05, 2024 (GLOBE NEWSWIRE) -- Grupo Aeroportuario del Pacífico, S.A.B. de C.V., (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) announces preliminary terminal passenger...
Industry Leader John Maraganore, Ph.D., Joins Cybrexa Therapeutics as Strategic Advisor
June 25, 2024 08:07 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., June 25, 2024 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Grupo Aeroportuario Del Pacifico Reports in May 2024 a Passenger Traffic Decrease of 2.3% Compared to 2023
June 04, 2024 19:43 ET
|
Grupo Aeroportuario del Pacífico, S.A.B. de C.V.
GUADALAJARA, Mexico, June 04, 2024 (GLOBE NEWSWIRE) -- Grupo Aeroportuario del Pacífico, S.A.B. de C.V., (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) announces preliminary terminal passenger...
Grupo Aeroportuario del Pacifico Reports in April 2024 a Passenger Traffic Decrease of 7.3% Compared to 2023
May 03, 2024 18:34 ET
|
Grupo Aeroportuario del Pacífico, S.A.B. de C.V.
GUADALAJARA, Mexico, May 03, 2024 (GLOBE NEWSWIRE) -- Grupo Aeroportuario del Pacífico, S.A.B. de C.V., (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) announces preliminary terminal passenger...
Grupo Aeroportuario del Pacifico Announces Results for the First Quarter of 2024
April 22, 2024 21:14 ET
|
Grupo Aeroportuario del Pacífico, S.A.B. de C.V.
GUADALAJARA, Mexico, April 22, 2024 (GLOBE NEWSWIRE) -- Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) reports its consolidated results for the first...